SNY vs TECH: fair value comparison
Sanofi and Bio-Techne Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SNY currently sits closer to the top of our discount ranking. TECH carries the stronger quality grade.
| SNY | TECH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $44.37 | $72.12 |
| 12-month range | $41.63–$47.40 | $50.79–$72.18 |
| Sector rank | #48 of 113 Healthcare | #52 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: SNY fair value analysis · TECH fair value analysis